Direkt zum Inhalt
Merck
Alle Fotos(1)

Dokumente

SCC062

Sigma-Aldrich

HMC-1.2 Human Mast Cell Line

Human

Synonym(e):

HMC-1 cell line

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise


About This Item

UNSPSC-Code:
41106514
eCl@ss:
32011203
NACRES:
NA.81

product name

HMC-1.2 Human Mast Cell Line, HMC-1.2 human mast cell line is a variant subline of the HMC-1 cell line and possesses both the V560G and D816V KIT mutations.

Biologische Quelle

human

Qualitätsniveau

Methode(n)

cell culture | mammalian: suitable

Versandbedingung

dry ice

Allgemeine Beschreibung

HMC-1 cell line was established from a patient with mast cell leukemia. HMC-1 cells are widely used in studies of human mast cell function because they exhibit many key characteristics of tissue mast cells, such as expression of histamine, tryptase, heparin and similar cell surface antigen-profile (1,2). Receptor tyrosine kinase KIT is expressed on mast cells and plays an important role in the proliferation, function and survival of mast cells. Activating mutations in KIT have been linked to dysregulated growth of mast cells and are associated with mast cell tumors and systemic mastocytosis. Two activating point mutations in KIT have been reported in the HMC-1 cell line (3). Both mutations convert the receptor to a constitutively tyrosine phosphorylated and active state, leading to growth factor-independent proliferation.

1. Nilsson, G, et al. (1994) Phenotypic Characterization of the Human Mast-Cell Line HMC-1. Scand. J. Immunol 39: 489-498.
2. Sundstrom, M, et al. (2003) Functional and phenotypic studies of two variants of a human mast cell line with a distinct set of mutations in the c-kit proto-oncogene. Immunology 108: 89-97.
3. Furitsu, T, et al. (1993) Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of c-kit product. J. Clin. Invest. 92(4): 1736-4.
HMC-1.1 (HMC-1(560)) and HMC-1.2 (HMC-1(560,816)) are two variant sublines of the HMC-1 cell line (2). HMC-1.1 possess the V560G mutation, but not the D816V mutation. HMC-1.2 possess both the V560G and D816V mutations and exhibits a higher proliferative rate than HMC-1.1. It has been suggested that the higher proliferative potential of HMC-1.2 may be attributed to the D816V mutation.

Beschreibung der Zelllinie

Cancer Cells

Anwendung

Research Category
Entzündung & Immunologie
This product is intended for sale and sold solely to academic institutions for internal academic research use per the terms of the “Academic Use Agreement” as detailed in the product documentation. For information regarding any other use, please contact licensing@emdmillipore.com.

Qualität

• Each vial contains ≥ 1X106 viable cells.
• Cells are tested by PCR and are negative for HPV-16, HPV-18, Hepatitis A, B, C and HIV-1 & 2 viruses.
• Cells are negative for mycoplasma contamination.
• Each lot of cells are genotyped by STR analysis to verify the unique identity of the cell line.

Lagerung und Haltbarkeit

Store in liquid nitrogen. The cells can be cultured for at least 10 passages after initial thawing without significantly affecting the cell marker expression and functionality.

Sonstige Hinweise

Concentration: Please refer to lot specific datasheet.

Haftungsausschluss

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
RESEARCH USE ONLY. This product is regulated in France when intended to be used for scientific purposes, including for import and export activities (Article L 1211-1 paragraph 2 of the Public Health Code). The purchaser (i.e. enduser) is required to obtain an import authorization from the France Ministry of Research referred in the Article L1245-5-1 II. of Public Health Code. By ordering this product, you are confirming that you have obtained the proper import authorization.

Lagerklassenschlüssel

10 - Combustible liquids

WGK

WGK 2

Flammpunkt (°F)

Not applicable

Flammpunkt (°C)

Not applicable


Analysenzertifikate (COA)

Suchen Sie nach Analysenzertifikate (COA), indem Sie die Lot-/Chargennummer des Produkts eingeben. Lot- und Chargennummern sind auf dem Produktetikett hinter den Wörtern ‘Lot’ oder ‘Batch’ (Lot oder Charge) zu finden.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Yunju Nam et al.
Cancers, 15(1) (2023-01-09)
c-KIT is a promising therapeutic target against gastrointestinal stromal tumor (GIST). In order to identify novel c-KIT inhibitors capable of overcoming imatinib resistance, we synthesized 31 novel thiazolo[5,4-b]pyridine derivatives and performed SAR studies. We observed that, among these substances, 6r
Rubí Vega-Hernández et al.
Microorganisms, 9(11) (2021-11-28)
Urinary tract infections (UTIs) are a public health problem in Mexico, and uropathogenic Escherichia coli (UPEC) is one of the main etiological agents. Flagella, type I fimbriae, and curli promote the ability of these bacteria to successfully colonize its host.
Poi Yi Aw Yong et al.
BMC complementary medicine and therapies, 23(1), 307-307 (2023-09-05)
Allergy is an inflammatory disorder affecting around 20% of the global population. The adverse effects of current conventional treatments give rise to the increased popularity of using natural food products as complementary and alternative medicine against allergic diseases. Stingless bee
Anu Gupta et al.
Molecular cancer therapeutics, 20(7), 1234-1245 (2021-05-06)
The majority of gastrointestinal stromal tumors (GIST) harbor constitutively activating mutations in KIT tyrosine kinase. Imatinib, sunitinib, and regorafenib are available as first-, second-, and third-line targeted therapies, respectively, for metastatic or unresectable KIT-driven GIST. Treatment of patients with GIST

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.